Contact

All Stories

  1. Fostering creativity through online creative collaborative group projects

    Article • Asian Association of Open Universities Journal, April 2020, Emerald

    Dr. Maria Rowena Del Rosario Raymundo

  2. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies

    Article • Cancer Medicine, July 2019, Wiley

    Dr. Maria Rowena Del Rosario Raymundo

  3. QR codes as mobile learning tools for labor room nurses at the San Pablo Colleges Medical Center

    Article • Interactive Technology and Smart Education, June 2017, Emerald

    Dr. Maria Rowena Del Rosario Raymundo

  4. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

    Article • The Lancet Infectious Diseases, October 2016, Elsevier

    Dr. Maria Rowena Del Rosario Raymundo

  5. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy:Post-hocanalysis from a randomized controlled trial

    Article • International Journal of Cancer, September 2016, Wiley

    Dr. Maria Rowena Del Rosario Raymundo

  6. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study

    Article • International Journal of Cancer, March 2016, Wiley

    Dr. Maria Rowena Del Rosario Raymundo

  7. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

    Article • The Lancet Oncology, July 2015, Elsevier

    Dr. Maria Rowena Del Rosario Raymundo

  8. Post HocAnalysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-...

    Article • Clinical and Vaccine Immunology, December 2014, ASM Journals

    Dr. Maria Rowena Del Rosario Raymundo

  9. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

    Article • The Lancet, December 2014, Elsevier

    Dr. Maria Rowena Del Rosario Raymundo

  10. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

    Article • BMC Infectious Diseases, October 2014, Springer Science + Business Media

    Dr. Maria Rowena Del Rosario Raymundo

  11. Correction: Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

    Article • PLOS One, December 2013, PLOS

    Dr. Maria Rowena Del Rosario Raymundo

  12. Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

    Article • PLOS One, November 2013, PLOS

    Dr. Maria Rowena Del Rosario Raymundo

  13. Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

    Article • The Journal of Infectious Diseases, October 2013, Oxford University Press (OUP)

    Dr. Maria Rowena Del Rosario Raymundo